Quick Answer
IRONWOOD PHARMACEUTICALS INC reported Total Revenue of $296.15 million for the year ending 2025.
- IRONWOOD PHARMACEUTICALS INC showed a decrease of -15.7% in Total Revenue from 2024 to 2025.
- This data is from IRONWOOD PHARMACEUTICALS INC's annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2009 to 2025 (19 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q4 2015: $53.31 million | Q1 2016: $66.04 million | Q2 2016: $54.35 million | Q3 2016: $66.11 million | Q4 2016: $87.46 million | Q1 2017: $52.17 million | Q1 2017: $52.17 million | Q2 2017: $65.08 million | Q2 2017: $65.08 million | Q3 2017: $86.83 million | Q3 2017: $86.83 million | Q4 2017: $94.21 million | Q4 2017: $94.21 million | Q1 2018: $69.16 million | Q1 2018: $69.16 million | Q2 2018: $81.11 million | Q3 2018: $65.69 million | Q4 2018: $130.69 million | Q1 2019: $68.73 million | Q2 2019: $102.22 million | Q3 2019: $131.17 million | Q4 2019: $126.30 million | Q1 2020: $79.94 million | Q2 2020: $89.43 million | Q3 2020: $103.47 million | Q4 2020: $116.68 million | Q1 2021: $88.85 million | Q2 2021: $104.03 million | Q3 2021: $103.75 million | Q4 2021: $117.13 million | Q1 2022: $97.53 million | Q2 2022: $97.23 million | Q3 2022: $108.64 million | Q4 2022: $107.20 million | Q1 2023: $104.06 million | Q2 2023: $107.38 million | Q3 2023: $113.74 million | Q4 2023: $117.55 million | Q1 2024: $74.88 million | Q2 2024: $94.40 million | Q3 2024: $91.59 million | Q4 2024: $90.55 million | Q1 2025: $41.14 million | Q2 2025: $85.24 million | Q3 2025: $122.06 million | Q4 2025: $47.71 million.
- Over the full 19 years of available data (2009 to 2025), IRONWOOD PHARMACEUTICALS INC's Total Revenue has grown by 762.9%.
- Historical annual values: Fiscal year 2025: $296.15 million | Fiscal year 2024: $351.41 million | Fiscal year 2023: $442.74 million | Fiscal year 2022: $410.60 million | Fiscal year 2021: $413.75 million | Fiscal year 2020: $389.52 million | Fiscal year 2019: $428.41 million | Fiscal year 2018: $346.64 million | Fiscal year 2017: $298.28 million | Fiscal year 2017: $298.28 million | Fiscal year 2016: $273.96 million | Fiscal year 2016: $273.96 million | Fiscal year 2015: $149.56 million | Fiscal year 2014: $76.44 million | Fiscal year 2013: $22.88 million | Fiscal year 2012: $150.25 million | Fiscal year 2011: $65.87 million | Fiscal year 2010: $43.86 million | Fiscal year 2009: $34.32 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: